Harris Teeter offering flu shots to customers
CHARLOTTE, N.C. Harris Teeter on Wednesday opened seasonal flu shot clinics in all of its 199 stores.
Working in cooperation with Mollen Immunization Clinics, the retailer is offering its customers a seasonal flu shot for $25 with their VIC card, or at no charge if they are a Medicare Part B, non-HMO recipient. For shoppers’ convenience, Harris Teeter is offering the option for the clinic nurse to bill insurances directly, pending the customer’s provider is included. The pneumococcal vaccine also is available for $60.
Registered nurses with Mollen will administer the shots in a temporary clinic set up inside Harris Teeter stores.
Allergan’s elevated intraocular pressure treatment gets nod from FDA
IRVINE, Calif. Allergan’s optimized reformulation of Lumigan has received approval from the Food and Drug Administration, the drug maker said Wednesday.
Lumigan 0.01% (bimatoprost ophthalmic solution) is a first-line therapy indicated for the reduction of elevated intraocular pressure with open-angle glaucoma or ocular hypertension, Allergan said. Lumigan 0.01% will be available in fourth quarter 2010 as the newest addition to Allergan’s comprehensive glaucoma portfolio.
"Lumigan 0.01% exemplifies Allergan’s commitment to developing medications for glaucoma patients that maximize efficacy while minimizing drug exposure,” said Scott Whitcup, Allergan’s EVP research and development and chief scientific officer.
Lilly’s Evista patents upheld in appeals court ruling
INDIANAPOLIS Eli Lilly’s method-of-use patents for its osteoporosis drug were declared valid by a federal court of appeals.
The drug maker said the Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company’s patents for Evista (raloxifene HCl tablets) are valid.
“Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. We will continue to vigorously defend our rights, in order to support the development of the next generation of innovative medicines,” said Robert Armitage, SVP and general counsel for Lilly.